Evaluation of Sulfasalazine as an Adjunctive Therapy in Treating Pulmonary Pre-XDR-TB : Efficacy, Safety, and Treatment Implication
© 2024 Fu et al..
Background: The rising prevalence and limited efficacy of treatments for pre-extensively drug-resistant tuberculosis (pre-XDR-TB) underscore an immediate need for innovative therapeutic options. A combination of host-directed therapy (HDT) and anti-TB treatment presents a viable alternative for pre-XDR-TB management. Sulfasalazine (SASP), by targeting the amino acid transport system xc (xCT), potentially reduces the intracellular Mycobacterium tuberculosis load and mitigates lung pathology, positioning it as a promising TB HDT agent. This study aims to assess the efficacy of SASP as a supplementary therapy for pre-XDR-TB.
Methods: A pilot study examined the safety and effectiveness of two 9-month short-course, all-oral regimens for pre-XDR-TB treatment: Bdq-regimen (consisting of Bdq, linezolid, cycloserine, clofazimine, and pyrazinamide) and SASP-regimen (comprising SASP, linezolid, cycloserine, clofazimine, and pyrazinamide). The primary endpoint was the incidence of unfavorable outcomes 12 months post-treatment.
Results: Of the 44 participants enrolled, 43 were assessable 12 months post-treatment. Culture conversion rates stood at 73.2% by Month 2 and escalated to 95.1% by Month 6. Overall, 88.4% (38/43) of the participants exhibited favorable outcomes, 85.2% (19/23) for the Bdq-regimen and 93.8% (14/15) for the SASP-regimen. The SASP-regimen group recorded no deaths or treatment failures.
Conclusion: Both 9-month short-course, all-oral regimens manifested commendable primary efficacy in treating pre-XDR-TB patients. The SASP-regimen emerged as effective, safe, well-tolerated, and cost-effective.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Infection and drug resistance - 17(2024) vom: 25., Seite 595-604 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fu, Liang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Host-directed therapy |
|---|
| Anmerkungen: |
Date Revised 24.02.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.2147/IDR.S443897 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36880609X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36880609X | ||
| 003 | DE-627 | ||
| 005 | 20240229150445.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2147/IDR.S443897 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1304.xml |
| 035 | |a (DE-627)NLM36880609X | ||
| 035 | |a (NLM)38390619 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fu, Liang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of Sulfasalazine as an Adjunctive Therapy in Treating Pulmonary Pre-XDR-TB |b Efficacy, Safety, and Treatment Implication |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 24.02.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2024 Fu et al. | ||
| 520 | |a Background: The rising prevalence and limited efficacy of treatments for pre-extensively drug-resistant tuberculosis (pre-XDR-TB) underscore an immediate need for innovative therapeutic options. A combination of host-directed therapy (HDT) and anti-TB treatment presents a viable alternative for pre-XDR-TB management. Sulfasalazine (SASP), by targeting the amino acid transport system xc (xCT), potentially reduces the intracellular Mycobacterium tuberculosis load and mitigates lung pathology, positioning it as a promising TB HDT agent. This study aims to assess the efficacy of SASP as a supplementary therapy for pre-XDR-TB | ||
| 520 | |a Methods: A pilot study examined the safety and effectiveness of two 9-month short-course, all-oral regimens for pre-XDR-TB treatment: Bdq-regimen (consisting of Bdq, linezolid, cycloserine, clofazimine, and pyrazinamide) and SASP-regimen (comprising SASP, linezolid, cycloserine, clofazimine, and pyrazinamide). The primary endpoint was the incidence of unfavorable outcomes 12 months post-treatment | ||
| 520 | |a Results: Of the 44 participants enrolled, 43 were assessable 12 months post-treatment. Culture conversion rates stood at 73.2% by Month 2 and escalated to 95.1% by Month 6. Overall, 88.4% (38/43) of the participants exhibited favorable outcomes, 85.2% (19/23) for the Bdq-regimen and 93.8% (14/15) for the SASP-regimen. The SASP-regimen group recorded no deaths or treatment failures | ||
| 520 | |a Conclusion: Both 9-month short-course, all-oral regimens manifested commendable primary efficacy in treating pre-XDR-TB patients. The SASP-regimen emerged as effective, safe, well-tolerated, and cost-effective | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Sulfasalazine | |
| 650 | 4 | |a host-directed therapy | |
| 650 | 4 | |a pre-extensive drug-resistant tuberculosis | |
| 650 | 4 | |a short-course | |
| 650 | 4 | |a treatment | |
| 700 | 1 | |a Wang, Wenfei |e verfasserin |4 aut | |
| 700 | 1 | |a Xiong, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Peize |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Hui |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Xilin |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Hancheng |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Qianting |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Zhaoqin |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Xinchun |e verfasserin |4 aut | |
| 700 | 1 | |a Deng, Guofang |e verfasserin |4 aut | |
| 700 | 1 | |a Cai, Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Shenjie |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Infection and drug resistance |d 2008 |g 17(2024) vom: 25., Seite 595-604 |w (DE-627)NLM209374322 |x 1178-6973 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2024 |g day:25 |g pages:595-604 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2147/IDR.S443897 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2024 |b 25 |h 595-604 | ||